CAMLG: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: CAMLG

NCBI ID: G819

CAMLG

CAMLG: A Potential Drug Target Or Biomarker for Various Diseases

CAMLG, short for cAMP-associated gene 163197, is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer. The gene is located on chromosome 16 and encodes a protein known as cAMP-associated protein 1 ( CAP1).

CAMLG is a member of the superfamily of G-protein-coupled receptors (GPCRs), a large family of transmembrane proteins that play a key role in cellular signaling. GPCRs are involved in a wide range of physiological processes, including sensory perception, neurotransmission, and hormone signaling. CAP1 is a 21-kDa protein that is expressed in various tissues and cell types, including muscle, nerve, heart, and cancer cells.

Studies have suggested that CAP1 may be involved in the regulation of cellular processes that are critical for human health, including cancer growth, angiogenesis, and inflammation. Several studies have also shown that CAP1 is involved in the development and progression of various diseases, including cancer . For example, CAP1 has been shown to be involved in the regulation of cell division, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels).

Due to these potential links to disease, CAP1 has been identified as a potential drug target or biomarker. Researchers have been investigating the potential uses of drugs that can modulate CAP1 activity in order to treat various diseases. One approach is to target CAP1 directly with small molecules, such as drugs that can bind to CAP1 and modulate its activity. Another approach is to identify CAP1-related proteins and use them as targets for drugs that can modulate their activity.

In addition to its potential as a drug target or biomarker, CAP1 has also been shown to be a promising biomarker for several diseases. For example, CAP1 has been used as a biomarker for cancer, with several studies showing that CAP1 levels are elevated in cancer tissue and associated with cancer progression. CAP1 has also been used as a biomarker for cardiovascular disease, with studies showing that CAP1 levels are elevated in the hearts of patients with hypertension and that CAP1 may be a predictor of cardiovascular event risk.

Overall, CAP1 is a gene that has significant potential as a drug target or biomarker for various diseases. Further research is needed to fully understand its role in cellular signaling and its potential as a therapeutic agent.

Protein Name: Calcium Modulating Ligand

Functions: Required for the post-translational delivery of tail-anchored (TA) proteins to the endoplasmic reticulum (PubMed:23041287, PubMed:24392163, PubMed:27226539). Together with GET1/WRB, acts as a membrane receptor for soluble GET3/TRC40, which recognizes and selectively binds the transmembrane domain of TA proteins in the cytosol (PubMed:23041287, PubMed:24392163, PubMed:27226539). Required for the stability of GET1 (PubMed:32187542). Stimulates calcium signaling in T cells through its involvement in elevation of intracellular calcium (PubMed:7522304). Essential for the survival of peripheral follicular B cells (By similarity)

The "CAMLG Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CAMLG comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets